AKBA vs. PBYI, URGN, RAPT, MRNS, WVE, TYRA, OCUL, ABVX, SPRY, and IMNM
Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Puma Biotechnology (PBYI), UroGen Pharma (URGN), RAPT Therapeutics (RAPT), Marinus Pharmaceuticals (MRNS), Wave Life Sciences (WVE), Tyra Biosciences (TYRA), Ocular Therapeutix (OCUL), ABIVAX Société Anonyme (ABVX), ARS Pharmaceuticals (SPRY), and Immunome (IMNM). These companies are all part of the "pharmaceutical preparations" industry.
Puma Biotechnology (NASDAQ:PBYI) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk, community ranking and dividends.
61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 23.7% of Puma Biotechnology shares are held by company insiders. Comparatively, 4.1% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Puma Biotechnology had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 3 mentions for Puma Biotechnology and 2 mentions for Akebia Therapeutics. Puma Biotechnology's average media sentiment score of 1.71 beat Akebia Therapeutics' score of 0.97 indicating that Akebia Therapeutics is being referred to more favorably in the news media.
Puma Biotechnology has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.
Puma Biotechnology has a net margin of 6.79% compared to Puma Biotechnology's net margin of -22.99%. Akebia Therapeutics' return on equity of 35.49% beat Puma Biotechnology's return on equity.
Puma Biotechnology received 127 more outperform votes than Akebia Therapeutics when rated by MarketBeat users. Likewise, 66.54% of users gave Puma Biotechnology an outperform vote while only 63.96% of users gave Akebia Therapeutics an outperform vote.
Puma Biotechnology presently has a consensus target price of $7.00, indicating a potential upside of 81.82%. Akebia Therapeutics has a consensus target price of $5.00, indicating a potential upside of 346.43%. Given Puma Biotechnology's higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Puma Biotechnology.
Puma Biotechnology has higher revenue and earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Puma Biotechnology beats Akebia Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Akebia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akebia Therapeutics Competitors List
Related Companies and Tools
